BHVN

Biohaven Ltd.

BHVN.US biohaven.com
12.79
-2.21 (-14.73%)
USD · NYSE
52-week range
7.48
18.57
Trading at 48% of the 52-week range
Market Cap
1.93B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.08
Div. Yield
N/A
% Institutions
96.66%
% Insiders
11.21%

1 Year

-8.7%

3 Year

-31.7%

10 Year

+75.2%
Description

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Company Information

Company Name
Biohaven Ltd.
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
ISIN: VGG1110E1079
CIK: 0001689813
Currency: USD
Full Time Employees: 274
Phone: 203 404 0410
Fiscal Year End: December
IPO Date: Sep 23, 2022
Description:

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Address:

215 Church Street, New Haven, CT, United States, 06510

People

Directors & Officers

Name Title Year Born
Dr. Vladimir Coric M.D. Chairman & CEO 1971
Mr. Matthew Buten Chief Financial Officer 1961
Ms. Kimberly Gentile Senior Vice President of Clinical Operations 1966
Dr. Bruce D. Car D.V.M., DACVP, Ph.D. Chief Innovation Officer 1962
Ms. Deb Young Senior Director of Regulatory Affairs & Operations NA
Mr. George C. Clark CPA VP & Chief Accounting Officer 1985
Mr. John McGill Chief Technology Officer NA
Ms. Jennifer Porcelli Vice President of Investor Relations NA
Mr. Warren Volles J.D. General Counsel & Chief Legal Officer NA
Mr. Clifford Bechtold M.S. President & GM of Biohaven Ireland Chief Compliance Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Nov 17, 2025 George C Clark N/A Purchase 17.00K $8.52 $144.84K
Nov 13, 2025 Gregory Bailey N/A Purchase 400.00K $7.50 $3.00M
Nov 13, 2025 John W Childs N/A Purchase 3.33M $7.50 $25.00M
Nov 13, 2025 Vlad Coric N/A Purchase 666.67K $7.50 $5.00M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 17.53M Mar 31, 2026 11.61% $0.07 1,145.92%
BlackRock Inc 11.22M Mar 31, 2026 7.43% $0.00 18.78%
Suvretta Capital Management, LLC 10.29M Mar 31, 2026 6.81% $2.22 0.00%
Stifel Financial Corp 9.94M Mar 31, 2026 6.58% $0.08 0.01%
State Street Corp 6.62M Mar 31, 2026 4.38% $0.00 15.78%
D. E. Shaw & Co LP 4.19M Jun 30, 2026 2.77% $0.03 47.17%
StemPoint Capital LP 3.19M Mar 31, 2026 2.11% $2.60 0.00%
Royalty Pharma Sub-Manager, LLC 2.94M Jun 30, 2026 1.94% $18.06 0.00%
Geode Capital Management, LLC 2.77M Mar 31, 2026 1.83% $0.00 15.70%
The Goldman Sachs Group Inc 2.51M Mar 31, 2026 1.66% $0.00 28.08%
Balyasny Asset Management LLC 2.45M Mar 31, 2026 1.62% $0.03 53.70%
FMR Inc 2.36M Mar 31, 2026 1.56% $0.00 -12.05%
Vanguard Portfolio Management, LLC 2.28M Mar 31, 2026 1.51% $0.00 0.00%
T. Rowe Price Associates, Inc. 2.22M Mar 31, 2026 1.47% $0.00 9.84%
AQR Capital Management LLC 1.98M Mar 31, 2026 1.31% $0.01 35.30%
TCG Crossover Management, LLC 1.78M Jun 30, 2026 1.18% $0.64 -61.57%
Cormorant Asset Management, LLC 1.76M Mar 31, 2026 1.17% $0.75 17,500.00%
Citadel Advisors Llc 1.72M Mar 31, 2026 1.14% $0.00 -1.20%
BNP Paribas Arbitrage, SA 1.54M Mar 31, 2026 1.02% $0.01 -26.24%
Qube Research & Technologies 1.54M Mar 31, 2026 1.02% $0.01 -1.92%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 4.00M 2.65% ▼ 1.06% Aug 31, 2026
2 iShares Russell 2000 ETF 3.42M 2.27% ▼ 0.57% Aug 31, 2026
3 Fidelity Select Biotechnology 2.18M 1.44% ▲ 0.00% Jul 31, 2026
4 Janus Henderson Global Life Sciences D 2.18M 1.44% ▼ 1.93% Apr 30, 2026
5 Janus Henderson Glb Life Scn I2 USD 2.00M 1.33% ▲ 0.54% May 31, 2026
6 HBM Healthcare Investments AG Ord 1.94M 1.28% ▲ 0.00% Jun 30, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 1.49M 0.99% ▲ 0.18% Jul 31, 2026
8 Fidelity Small Cap Index 1.45M 0.96% ▲ 23.79% Jun 30, 2026
9 Janus Henderson Global Life Sciences 1.31M 0.86% ▼ 41.16% Jun 30, 2026
10 Janus Global Life Science AUSD 1.27M 0.84% ▼ 38.60% Jun 30, 2026

Financial Highlights

Market Cap: $1.93B
EBITDA: $-520.11M
Book Value: $0.08
Earnings/Share: $-4.55
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -71.98%
ROE (TTM): -799.46%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $2.29B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 151.04M
Shares Float: 116.57M
% Insiders: 11.21%
% Institutions: 96.66%
Short % Float: 15.09%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-4.14M
Gross Profit
subtotal
$-4.14M
SG&A
adjust
$-106.17M
R&D
adjust
$-635.07M
Operating Income
subtotal
$-745.38M
Other / Non-Operating Items
adjust
$6.56M
Net Income
subtotal
$-738.82M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BHVN.US!